Mallin, Mikaela M.
Kim, Nicholas
Choudhury, Mohammad Ikbal
Lee, Se Jong
An, Steven S.
Sun, Sean X.
Konstantopoulos, Konstantinos
Pienta, Kenneth J.
Amend, Sarah R.
Funding for this research was provided by:
New Jersey Alliance for Clinical and Translational Science (UL1TR0030117)
National Institutes of Health (P01HL114471, RO1GM134542)
National Cancer Institute (U54CA143803)
Prostate Cancer Foundation
US Department of Defense (W81XWH-20-10353)
Patrick C. Walsh Prostate Cancer Research Fund
Article History
Received: 4 August 2022
Accepted: 2 June 2023
First Online: 16 June 2023
Declarations
:
: S.S.A has no disclosures. S.X.S has no disclosures. K.K has no disclosures. K.J.P. discloses that he is a consultant to Cue Biopharma, Inc., an equity holder in PEEL therapeutics, and a founder and equity holder in Keystone Biopharma, Inc. S.R.A. discloses that she is an equity holder in Keystone Biopharma, Inc.